Description

Jazz Pharmaceuticals: Modeyso Is Beating Expectations—Is This a Surprise Launch That Can Reset the Revenue Story?

Jazz Pharmaceuticals reported strong financial and operational performance in 2025, marking their 21st consecutive year of topline revenue growth. The company achieved record total revenue of $4.3 billion, with the fourth quarter contributing $1.2 billion, reflecting a 10% year-over-year increase, making it their highest revenue quarter ever. This growth was driven by successful product launches and strategic acquisitions. One key highlight was the acquisition of Chimerix and the subsequent approval and launch of Modeyso, a therapy for a rare brain tumor. Since its launch in August 2025, Modeyso generated $48 million in revenue, addressing a significant unmet need. Additionally, the approval of Zepzelca for use in combination with atezolizumab in first-line maintenance for small cell lung cancer has expanded its market. Jazz continues to build on its rare disease strategy, aiming to enhance existing franchises and venture into new rare disease areas.